PTC Therapeutics (PTCT) PT Lowered to $46 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts PTCT Hot Sheet
Price: $60.59 -3.89%
Rating Summary:
17 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
17 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams lowered the price target on PTC Therapeutics (NASDAQ: PTCT) to $46.00 (from $60.00) while maintaining a Sector Perform rating.
You May Also Be Interested In
- PTC Therapeutics (PTCT) PT Lowered to $106 at Raymond James
- Tango Therapeutics Inc. (TNGX) PT Raised to $55 at Stifel
- Graco Inc. (GGG) PT Lowered to $80 at DA Davidson
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
